Jeffrey Heier reports 10,502-share sell-to-cover; retains 249,409 OCUL shares
Rhea-AI Filing Summary
Insider sale to cover taxes on vested RSUs: The Chief Scientific Officer, Jeffrey S. Heier, reported sales of 10,502 shares of Ocular Therapeutix common stock on 10/02/2025 under a pre-existing automatic sale instruction. The disposals were non-discretionary sell-to-cover transactions tied to the vesting of restricted stock units on 10/01/2025.
Those shares were sold in multiple trades at prices ranging from $10.99 to $11.0866, with a reported weighted-average price of $11.04. After the sales, the reporting person beneficially owned 249,409 shares directly.
Positive
- Sale was non-discretionary under a pre-existing automatic instruction adopted on 4/09/2024
- Reporting person retained significant ownership with 249,409 shares after the transactions
Negative
- Shares were sold (10,502) which reduces insider ownership and could be perceived negatively by some investors
- Weighted-average sale price was $11.04, implying realized proceeds matched market at those execution prices
Insights
Non-discretionary sell-to-cover after RSU vesting, not an active trading signal.
The sales were executed under a durable automatic sale instruction adopted on 4/09/2024 to satisfy tax-withholding from the vesting of restricted stock units on 10/01/2025. This indicates the transactions were procedural and tied to compensation mechanics rather than discretionary market-timing by the officer.
Dependence on plan terms and vesting schedules is the main risk to interpreting intent; monitor future filings for any discretionary sales or further plan-based disposals within the next 12 months.
Sale size is small relative to total ownership — limited market impact.
The reported sale of 10,502 shares reduced holdings but left the officer with 249,409 shares, so the transaction represents a modest portion of reported direct ownership. The price range reported ($10.99–$11.0866) and weighted-average $11.04 suggest executions across several trades rather than a single large block.
Watch for additional Form 4s if successive sell-to-cover events occur at future vesting dates; any clustering of discretionary sales would be relevant within a 12-month window.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 10,502 | $11.04 | $116K |
Footnotes (1)
- Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 1, 2025. The sales do not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.99 to $11.0866, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
